Enovis

ENOV

Market cap $1.42B

DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.

The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis

The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.

Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript

Enovis (ENOV) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.81 per share a year ago.

Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell (OMCL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.26 per share a year ago.

Enovis (ENOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.